Carlyle Group
CG
$45.43
+0.66%
The Carlyle Group is one of the world's largest alternative asset managers, operating across global private equity, credit, and investment solutions with $476.9 billion in total assets under management. The firm is a dominant player in the private capital markets, distinguished by its global scale, diversified investment platform, and deep institutional relationships. The current investor narrative centers on the firm's strategic expansion into new areas like asset-backed finance and wealth management, as evidenced by recent acquisitions, while the stock contends with significant underperformance relative to the broader market and concerns over fundraising and realization activity in a challenging macroeconomic environment.…
CG
Carlyle Group
$45.43
Related headlines
Investment Opinion: Should I buy CG Today?
Rating: Hold. The core thesis is that Carlyle presents a high-risk, potentially high-reward turnaround story, but the current evidence of operational instability and negative cash flow warrants caution until a clearer recovery trajectory emerges.
Supporting Evidence: The primary valuation metric, the forward P/E of 8.7x, is compelling if the $6.16 EPS estimate is achieved, representing a significant discount to its own trailing multiple. However, this optimism is contradicted by severe earnings volatility (Q3 net margin of 0.1% vs. Q4's 19.4%) and a negative TTM free cash flow of -$1.73B. The stock trades near its 52-week low, but the lack of a clear fundamental catalyst and persistent technical downtrend (-14.65% over 3 months) offset the apparent value.
Risks & Conditions: The two biggest risks are the unsustainable cash burn and the high operational leverage to economic cycles. This Hold rating would upgrade to a Buy if: 1) The company reports two consecutive quarters of positive free cash flow, 2) Forward EPS estimates are validated with stable quarterly net income above $300M, or 3) The stock holds above $43.19 support and breaks above the $55 resistance on sustained volume. It would downgrade to a Sell if: 1) TTM free cash flow remains deeply negative for another quarter, 2) Debt-to-equity climbs above 2.5, or 3) The stock decisively breaks below $43.19. The stock is fairly valued to slightly undervalued on forward earnings estimates but overvalued on trailing cash flow and quality of earnings.
Sign up to view all
CG 12-Month Price Forecast
Carlyle is a classic 'show me' story trading on hope (low forward P/E) versus reality (erratic fundamentals, cash burn). The neutral stance reflects the high uncertainty: the valuation is cheap for a reason. The path to a bullish re-rating requires demonstrable proof of earnings stability and positive cash flow generation, which recent quarters have not provided. The stance would upgrade to bullish on two consecutive quarters of >$200M net income and positive FCF. It would turn bearish on a break below $43 support coupled with another quarter of sub-$50M net income.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Carlyle Group's 12-month outlook, with a consensus price target around $59.06 and implied upside of +30.0% versus the current price.
Average Target
$59.06
1 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
1
covering this stock
Price Range
$36 - $59
Analyst target range
Insufficient analyst coverage available. The data indicates only one analyst providing estimates, with no consensus price target or recommendation distribution presented. This limited coverage is atypical for a firm of Carlyle's market cap ($21.3 billion) and suggests it may be under-followed relative to its peers, which can lead to higher volatility and less efficient price discovery. The available institutional ratings from recent months show a pattern of reiterated Buy/Outperform ratings from firms like UBS, TD Cowen, and Barclays, indicating maintained bullish sentiment among those who do cover it, but the lack of a broad consensus makes it difficult to gauge overall market expectations.
Bulls vs Bears: CG Investment Factors
The evidence currently tilts bearish, driven by severe fundamental volatility, a negative cash flow trend, and a persistent technical downtrend. However, the bull case is anchored in a deeply discounted forward valuation and the company's strategic efforts to pivot its business model. The single most important tension in the investment debate is whether Carlyle's forward P/E of 8.7x represents a compelling value trap or a genuine mispricing. This hinges entirely on the company's ability to stabilize its wildly fluctuating earnings and convert its massive AUM into consistent, high-margin fee income and realizations, a feat it has failed to demonstrate in recent quarters.
Bullish
- Deeply Discounted Forward P/E: The forward P/E of 8.7x is significantly lower than the trailing P/E of 26.3x, reflecting a substantial discount if the company achieves its forward EPS estimate of $6.16. This forward multiple suggests the market has priced in severe pessimism, offering a potential value opportunity if earnings stabilize.
- Strategic Expansion into Growth Segments: Recent acquisitions, such as the multibillion-dollar deal for MAI and the Camino Natural Resources asset purchase, validate Carlyle's strategic pivot into asset-backed finance and wealth management. These moves aim to diversify revenue streams beyond traditional private equity, which is critical as fundraising remains challenged.
- Strong Institutional Support & Scale: With $476.9 billion in total AUM, Carlyle retains immense scale and deep institutional relationships, providing a stable fee-related earnings base. Recent analyst ratings from UBS, TD Cowen, and Barclays have reiterated Buy/Outperform, indicating maintained bullish sentiment among key followers.
- Oversold Technical Condition: The stock trades at $45.43, only 17% above its 52-week low of $43.19 and 35% below its high of $69.85, indicating deeply oversold territory. The severe -16.25% relative underperformance vs. the SPY over the past month suggests negative sentiment is extreme, potentially setting up for a technical rebound.
Bearish
- Severe Earnings & Revenue Volatility: Profitability is highly erratic, with Q3 2025 net income plunging to $0.9M from $595.7M a year prior, and Q4 2025 gross margin collapsing to 54.5% from 83.1% in Q2 2025. This inconsistency, coupled with a -$1.73B TTM free cash flow burn, raises serious questions about earnings quality and sustainable cash generation.
- Persistent Technical Downtrend & High Beta: The stock is in a pronounced downtrend, down 14.65% over three months and 12.16% over six months, with a high beta of 1.887 amplifying downside moves. This persistent selling pressure and underperformance (-25.3% vs. SPY over 6 months) reflect a complete lack of bullish catalysts and significant negative momentum.
- High Financial Leverage: A debt-to-equity ratio of 2.41 indicates a highly leveraged balance sheet, which increases financial risk and interest expense sensitivity in a rising rate environment. This leverage compounds the risk posed by the company's negative free cash flow.
- Limited Analyst Coverage & Visibility: Only one analyst provides estimates, resulting in no consensus price target. This limited coverage for a $21.3B market cap firm leads to higher volatility and less efficient price discovery, increasing uncertainty for investors.
CG Technical Analysis
The stock is in a pronounced downtrend, having declined 14.65% over the past three months and 12.16% over six months, culminating in a current price of $45.43. This places it near the bottom of its 52-week range, trading at approximately 17% above its 52-week low of $43.19 and 35% below its high of $69.85, indicating the stock is in a deeply oversold territory and facing persistent selling pressure. Recent momentum is decisively negative, with a sharp 11.41% drop over the past month, which accelerates the longer-term downtrend; this is underscored by severe relative weakness, as the stock has underperformed the SPY by 16.25 percentage points over the same period, signaling a complete lack of bullish catalysts. Key technical support is clearly defined at the 52-week low of $43.19, while resistance sits near the recent breakdown level around $54-55; a sustained break below $43.19 would likely trigger another leg down, while a recovery above $55 is needed to suggest a trend reversal. The stock's high beta of 1.887 confirms it is nearly 90% more volatile than the market, which amplifies both downside risk and potential for sharp rebounds, but necessitates careful risk management given the current bearish trajectory.
Beta
1.89
1.89x market volatility
Max Drawdown
-34.9%
Largest decline past year
52-Week Range
$44-$70
Price range past year
Annual Return
+2.3%
Cumulative gain past year
| Period | CG Return | S&P 500 |
|---|---|---|
| 1m | -11.4% | +4.4% |
| 3m | -14.7% | +9.3% |
| 6m | -12.2% | +10.5% |
| 1y | +2.3% | +28.8% |
| ytd | -25.4% | +9.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CG Fundamental Analysis
Revenue growth has been highly volatile and recently decelerated, with Q4 2025 revenue of $1.84 billion representing a dramatic 98.8% year-over-year increase, but this surge is misleading as it follows a weak prior-year quarter; sequentially, revenue fell from $1.18 billion in Q2 and $780.5 million in Q3, indicating inconsistent performance. The company is profitable on a net income basis, reporting $358.1 million in Q4 2025 with a net margin of 19.4%, but profitability is erratic, as evidenced by a mere $0.9 million net income in Q3 2025; gross margin was 54.5% in Q4, down significantly from 83.1% in Q2, reflecting substantial compression likely due to mix shifts in revenue segments like performance allocations. The balance sheet shows a high degree of financial leverage with a debt-to-equity ratio of 2.41, which increases risk in a rising rate environment; while the current ratio is an exceptionally high 15.72, indicating strong short-term liquidity, trailing twelve-month free cash flow is deeply negative at -$1.73 billion, suggesting the company is consuming, not generating, cash to fund its operations and investments, raising questions about sustainable internal funding.
Quarterly Revenue
$1.8B
2025-12
Revenue YoY Growth
+0.98%
YoY Comparison
Gross Margin
+0.54%
Latest Quarter
Free Cash Flow
$-1.7B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CG Overvalued?
Given the company's positive net income, the primary valuation metric is the P/E ratio. The trailing P/E is 26.3x, while the forward P/E is significantly lower at 8.7x, indicating the market expects a substantial earnings recovery, with forward EPS estimates averaging $6.16 compared to a trailing EPS of just $0.038. Compared to sector averages, the trailing P/E of 26.3x is likely at a premium to traditional asset managers, though a direct industry average is not provided in the data; the forward P/E of 8.7x, however, appears discounted if the earnings estimates materialize, suggesting the market is pricing in significant skepticism. Historically, the stock's own P/E ratio has fluctuated wildly, from a high of over 6,271x during a low-earnings quarter in Q3 2025 to a low in the single digits; the current trailing multiple of 26.3x sits below the 14.8x reported for Q4 2025 in the historical ratios, indicating the valuation has compressed alongside the price decline, potentially offering value if the fundamental outlook stabilizes.
PE
26.3x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range -29x~6272x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
23.9x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Carlyle faces significant financial risk from its high debt-to-equity ratio of 2.41, which amplifies downside in a higher-for-longer rate environment. Operationally, earnings are highly volatile, with net income swinging from $595.7M in Q3 2024 to $0.9M in Q3 2025, making forecasting difficult. Most critically, trailing twelve-month free cash flow is deeply negative at -$1.73 billion, indicating the business is consuming cash to fund operations and growth, raising sustainability concerns if this trend persists.
Market & Competitive Risks: The stock's high beta of 1.887 makes it nearly 90% more volatile than the market, amplifying downside during risk-off periods, as evidenced by its 35% drawdown from its 52-week high. As a private equity firm, its revenue is heavily exposed to cyclical fundraising and realization markets, which are currently challenged. Valuation compression is a key risk; while the forward P/E of 8.7x appears cheap, the trailing P/E of 26.3x is likely at a premium to more stable asset managers, leaving room for further multiple contraction if earnings disappoint.
Worst-Case Scenario: A continuation of the current downtrend, triggered by another quarter of weak earnings, a significant slowdown in fundraising, and a broader market sell-off, could see the stock break its key technical support at the 52-week low of $43.19. Given the high beta and negative cash flow, a re-test of the low is plausible, representing a -5% downside from the current price. A more severe scenario, involving a credit market dislocation that impairs its leveraged portfolio and forces asset sales, could push the stock toward the $35-40 range, implying a potential loss of -12% to -23% from current levels.
FAQ
The key risks are, in order of severity: 1) Financial Risk: High debt-to-equity (2.41) and deeply negative free cash flow (-$1.73B TTM) threaten financial flexibility. 2) Operational Risk: Extreme earnings and margin volatility (Q3 net margin 0.1% vs. Q4 19.4%) makes the business unpredictable. 3) Market Risk: A high beta of 1.887 means the stock will fall more than the market in downturns, as seen in its 35% drawdown from highs. 4) Business Model Risk: Revenue is tied to cyclical private capital markets, which are currently facing macroeconomic headwinds for fundraising and exits.
Our 12-month outlook outlines three scenarios. The Base Case (50% probability) sees the stock trading between $48 and $55, as it remains range-bound amid ongoing earnings volatility. The Bull Case (25% probability), targeting $65-$70, requires a successful business turnaround and improved market conditions. The Bear Case (25% probability), targeting $38-$43, involves further operational deterioration and a break of key support. The Base Case is most likely, predicated on the assumption that the company avoids a catastrophic quarter but fails to deliver a convincing recovery, leaving the stock to oscillate within its recent wide range.
CG's valuation presents a paradox. On a forward P/E basis of 8.7x (based on estimated EPS of $6.16), the stock appears deeply undervalued, especially for a firm with its scale. However, on a trailing P/E basis of 26.3x and, more importantly, a negative price-to-cash-flow due to -$1.73B in TTM FCF, it appears overvalued. The market is paying a discount for expected future earnings recovery but is skeptical given the company's recent inability to generate consistent profits or cash. Relative to its own history and the volatility of its results, the stock is fairly valued at current levels, trading the potential for a sharp recovery against the risk of further deterioration.
CG is a high-risk, potentially high-reward stock that may be suitable for speculative investors, but is not a 'good buy' for most. The forward P/E of 8.7x and price near 52-week lows suggest deep value, but this is offset by severe earnings volatility, negative free cash flow of -$1.73B, and a high debt load. The biggest downside risk is a continuation of operational instability leading to a break below $43 support. It could be a good buy for a risk-tolerant investor who believes the company will stabilize its earnings, but most should wait for concrete evidence of a turnaround, such as two consecutive quarters of positive cash flow.
CG is unsuitable for short-term trading due to its high beta (1.887) and lack of near-term positive catalysts, which could lead to significant losses. It is only suitable for long-term, patient investors with a minimum 3-5 year horizon who are betting on a successful strategic pivot and eventual earnings stabilization. The company's growth initiatives in asset-backed finance and wealth management will take years to materially impact the financials. Given the high volatility and operational uncertainty, it should only constitute a small, speculative portion of a diversified portfolio.